Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
Objective To evaluate the efficacy and safety of tislelizumab combined with chemotherapy in the treatment of urothelial carcinoma in the real word. Methods We enrolled 32 patients with urothelial carcinoma who were treated with tislelizumab and chemotherapy (gemcitabine/cisplatin or paclitaxel). The...
Main Authors: | WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-07-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1340 |
Similar Items
-
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
by: Jingwen Zhang, et al.
Published: (2024-02-01) -
Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
by: Meng Yang, et al.
Published: (2024-02-01) -
The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching
by: Zhimin Gao, et al.
Published: (2023-12-01) -
The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
by: Fuxin Han, et al.
Published: (2023-12-01) -
Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
by: Qi Jiang, et al.
Published: (2023-05-01)